Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study

Pediatr Rheumatol Online J. 2026 Jan 22. doi: 10.1186/s12969-026-01184-w. Online ahead of print.

Dominic S Bräm¹, Verena Gotta^{2

3}, Gilbert Koch², Klervi Golhen², Andreas Woerner⁴, Andrew Atkinson^{2

5

6}, Johannes N van den Anker⁷, Marc Pfister^#², Tatjana Welzel^#^{2

4

5

8}

¹ Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel UKBB, Spitalstrasse 33, Basel, CH-4056, Switzerland. Dominic.braem@ukbb.ch.
² Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel UKBB, Spitalstrasse 33, Basel, CH-4056, Switzerland.
³ Clinical Pharmacy, University Children's Hospital Basel UKBB, Basel, Switzerland.
⁴ Paediatric Rheumatology, University Children's Hospital Basel UKBB, Basel, Switzerland.
⁵ Paediatric Research Centre, University Children's Hospital Basel UKBB, Basel, Switzerland.
⁶ Division of Infectious Diseases, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
⁷ Division of Clinical Pharmacology, Children's National Hospital, District of Columbia, Washington, USA.
⁸ Programme area Epidemiology and Health Services Research, German Rheumatology Research Center, a Leibniz-Institute, Berlin, Germany.

^# Contributed equally.

No abstract available

Keywords: Drug exposure; Personalized treatment; Pharmacodynamics; Pharmacokinetics; Remission; Tapering; Target range.